Breast cancer screening and diagnostic tests help doctors detect and evaluate breast abnormalities at different stages. This guide covers the main imaging methods, including mammography, ultrasound, and MRI, as well as biopsy and receptor testing used to confirm and characterize breast cancer. It also explains screening recommendations for different risk groups and the breast cancer diagnostic pathway in Germany.

Breast Cancer Diagnosis and Screening: Tests, Imaging and Biopsy

Breast cancer screening helps detect cancer at an early stage, sometimes before any noticeable symptoms appear. Mammography is the main screening test, while ultrasound and MRI may be used in certain situations depending on a person's age, breast density, and risk level.

If screening or a physical examination shows something unusual, diagnostic tests can help doctors determine what the finding means. This may include additional imaging and, when necessary, a biopsy to confirm whether cancer is present.

Breast Cancer Screening and Early Detection

Breast cancer screening aims to find cancer early, often before symptoms develop, when more treatment options may be available [1].

A screening mammogram checks both breasts on a routine schedule in someone without symptoms. Diagnostic imaging, on the other hand, investigates a specific complaint [2].

An abnormal screening result does not confirm cancer on its own. It generally means:

• Additional imaging views may be needed to get a clearer picture.
• Another test, such as ultrasound, may be used to look closer.
• Tissue sampling (biopsy) may be recommended if the finding still looks suspicious.
• Most abnormal screening results turn out not to be cancer.

Screening recommendations depend on age and a person's individual risk. This means the recommended starting age and screening interval can differ between people.

Breast Cancer Screening Guidelines and Recommended Age

In the United States, screening recommendations vary between organizations. The US Preventive Services Task Force recommends biennial mammography for women aged 40 to 74 years at average risk, while other organizations recommend different screening intervals based on age and risk [2].

In its 2024 update, the USPSTF expanded its recommendation for routine biennial mammography to begin at age 40; previously, screening before age 50 was based on individual decision-making [2].

As women age, the balance between benefit and potential harm from repeated mammography gradually shifts. Clinicians often revisit screening decisions individually once a woman reaches her mid-seventies.

Personal risk factors can place someone in an increased-risk category with different starting ages and imaging needs, covered in the next section.

Screening for People at Higher Risk

Some people have a higher-than-average risk of breast cancer and may need to begin screening earlier or have additional imaging [3].

• A strong family history of breast or ovarian cancer.
• An inherited pathogenic variant such as BRCA1 or BRCA2.
• Previous chest radiation between roughly ages 10 and 30.

For people with a confirmed BRCA1 or BRCA2 pathogenic variant, high-risk screening commonly includes annual breast MRI beginning around age 25, with mammography added around age 30. However, the exact schedule may vary by guideline and individual risk.

Breast MRI is generally added to mammography rather than replacing it in these higher-risk groups. A genetics specialist or breast-health clinician can help determine whether earlier or supplemental imaging is appropriate.

Breast Cancer Screening Tests and Imaging

Several imaging methods examine breast tissue. Which test is used depends on factors such as age, breast density, personal risk, and whether doctors are screening for cancer or investigating a specific finding.

Mammography for Breast Cancer Screening

Mammography, an X-ray image of the breast, remains the primary imaging method with the strongest population-level evidence for reducing breast cancer mortality [2]. A mammogram can detect:

• Masses or lumps in the breast tissue.
• Areas of distorted breast tissue.
• Calcifications: small calcium deposits, some of which are linked to early cancer.

Mammography's sensitivity varies with breast density. It performs less well in dense breast tissue, where overlapping fibroglandular tissue can obscure a small mass [4]. When a screening mammogram shows an abnormal finding, the next step is usually additional views or targeted ultrasound.

Breast Ultrasound for Screening and Evaluation

Breast ultrasound uses sound waves instead of radiation. It is especially useful for characterizing a finding, such as determining whether a mass is solid or fluid-filled. Supplemental ultrasound may detect additional cancers in some women with dense breasts, but it can also increase false-positive findings and lead to additional imaging or biopsies [4].

Dense breast tissue alone does not automatically mean supplemental MRI or ultrasound is required; recommendations vary according to overall risk and the guideline being followed. Ultrasound is also commonly used to evaluate breast findings in younger women and during pregnancy because it does not use ionizing radiation. Mammography can also be performed during pregnancy when clinically indicated. It is not typically used alone for population-wide screening. Instead, it complements mammography rather than replacing it.

Breast MRI for Screening and Diagnosis

Contrast-enhanced breast MRI is among the most sensitive breast imaging methods available, particularly for women at elevated risk [4]. MRI is therefore mainly used for screening people with a high lifetime risk of breast cancer, particularly confirmed BRCA1 or BRCA2 carriers [3]. In selected cases, MRI can also help assess the extent of a newly diagnosed cancer or clarify a finding when mammography and ultrasound are inconclusive. MRI is not a routine, first-line screening test for average-risk women. Its high sensitivity comes with lower specificity, which can lead to extra imaging or biopsies for findings that prove benign.

Differences between Mammography, Ultrasound, and MRI

These tests are used for different reasons, and doctors may combine them when one test does not provide enough information. Table 1 summarizes the key differences.

Using more than one imaging method can improve detection in some situations, although it may also increase false-positive results [4].

Breast Cancer Diagnosis: From Imaging to Biopsy

A suspected breast abnormality may be noticed by the patient, found during a clinical examination, or detected on a screening test. Doctors then use imaging and, when needed, biopsy to determine what the finding represents [5].

• Clinical assessment.
• Diagnostic imaging.
• Biopsy.
• Pathological analysis [5].

Clinical Breast Examination

A clinical breast examination involves a clinician visually inspecting and manually palpating the breasts and nearby lymph node areas for abnormalities. This can include a palpable lump, skin changes, or nipple discharge or retraction. Physical examination provides useful information, but it cannot, on its own, confirm or rule out cancer. Any suspicious finding on examination needs to be followed by imaging and, in most cases, tissue sampling before a diagnosis is established.

Diagnostic Breast Imaging

Diagnostic imaging differs from screening imaging in that it targets a specific area of concern rather than surveying the whole breast on a routine schedule. A diagnostic mammogram typically includes additional or magnified views, with targeted ultrasound frequently used alongside it to characterize the finding. Breast MRI may be considered in selected situations, for example to assess disease extent in a newly diagnosed cancer or when mammography and ultrasound remain unclear [4].

Breast Biopsy and Pathology

A biopsy, removal of a small tissue sample for laboratory analysis, is generally recommended when imaging shows a finding suspicious enough to warrant tissue confirmation [6].

Common biopsy approaches include:

• Core needle biopsy is commonly preferred for suspicious breast findings, with imaging guidance chosen according to how the lesion is best visualized.
• Mammographic (stereotactic) or MRI-guided biopsy  used less commonly, for findings only visible on those tests.
• Fine-needle aspiration is used selectively, for example for certain cystic or lymph-node findings.
• Surgical excisional biopsy is used in selected cases [6].

A pathologist examines the tissue to determine whether cancer is present and assesses features such as its histologic type and grade [7].

Pathology results are also checked against the imaging findings to ensure concordance. If the biopsy result does not adequately explain the imaging finding, the radiologist and pathologist may recommend repeat biopsy or, in some cases, surgical excision [6].

Breast Cancer Biomarker and Receptor Testing

Once breast cancer is confirmed on biopsy, the same tissue sample is typically tested further to characterize the tumor's biological features.

ER, PR and HER2 Testing

Estrogen receptor (ER), progesterone receptor (PR), and HER2 testing are routinely assessed in newly diagnosed invasive breast cancer [8] [13].

The results indicate:

• ER and PR status: whether hormones influence the tumor's growth.
• HER2 status: whether the tumor overexpresses the HER2 protein or carries HER2 gene amplification.
• How the cancer is classified, for example, hormone receptor-positive, HER2-positive, or triple-negative [8].

Additional Biomarker and Molecular Testing

For some patients with early-stage, hormone receptor-positive, HER2-negative breast cancer, additional multigene genomic assays may help estimate recurrence risk and inform adjuvant chemotherapy decisions [9].

These tests are not required for everyone and are used in selected clinical scenarios based on tumor biology, stage, lymph-node status, menopausal status, and other clinical factors. Genetic counseling and testing may be recommended when personal or family history suggests an inherited predisposition to breast cancer, with testing guided by the individual's risk and applicable guidelines [3].

Quick Reference: U.S. Screening Recommendations and High-Risk Groups

Table 2 summarizes selected U.S. screening recommendations and examples of high-risk groups discussed above. Individual recommendations should be based on personal risk and the applicable clinical guideline.

Breast Cancer Screening and Diagnosis in Germany

Germany offers a structured pathway for both breast cancer screening and diagnostic evaluation. The national Mammography Screening Programme invites women aged 50 to 75 for mammography every two years, in line with European quality standards [10].

People who have a specific breast concern can also receive diagnostic imaging, targeted ultrasound, or biopsy outside the organized screening program.

International patients often have access to certified breast centers (Brustzentren) offering multidisciplinary assessment. These centers are voluntarily certified against national requirements set by the German Cancer Society and German Society of Senology, with independent audits confirming that radiologists, pathologists, breast surgeons, and oncologists jointly review findings for the same patient, rather than in disconnected appointments [12].

German breast centers typically offer:

• Advanced imaging, including digital mammography, ultrasound, and MRI.
• On-site or closely affiliated pathology services.
• Biopsy analysis and receptor testing.
• Additional molecular testing where indicated.
• Review of existing scans and reports, to help avoid unnecessary repeat testing [12].

Obtaining a second medical opinion is a well-established option in Germany. Evidence from the United States illustrates why: In one study of 70 patients specifically seeking a second opinion, a multidisciplinary review led to a diagnostic change in 42.8% of cases. A similar structured, multidisciplinary review is a key feature of certified breast centers in Germany, though its impact on any individual case will vary [11].

If you are preparing for a consultation, bring:

• Imaging files or discs.
• Written radiology and biopsy reports.
• Prior pathology or treatment summaries.

To access certified breast centers and tailored multidisciplinary care in Germany, patients can explore their options through Treatment in Germany.

References

1. American Cancer Society Early Detection and Diagnosis of Breast Cancer

2. US Preventive Services Task Force  Screening for Breast Cancer: 2024 Recommendation Statement (JAMA)

3. NCCN Guidelines  Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

4. American College of Radiology  Appropriateness Criteria: Supplemental Breast Cancer Screening Based on Breast Density (2024 Update)

5.Leitlinienprogramm Onkologie  AWMF  S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms

6. NCCN Clinical Practice Guidelines  Breast Cancer Screening and Diagnosis (JNCCN)

7. National Cancer Institute  Surgical Pathology Reports Fact Sheet

8. ASCO–College of American Pathologists Guideline Update  HER2 Testing in Breast Cancer

9. ASCO Guideline Update Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

10. Bundesamt für Strahlenschutz (BfS)  The German Mammography Screening Programme

11. Garcia D, et al.  The Value of a Second Opinion for Breast Cancer Patients Referred to an NCI-Designated Cancer Center (Annals of Surgical Oncology)

12. Brucker SY, et al.  Certification of Breast Centres in Germany: Proof of Concept for a Prototypical Example of Quality Assurance in Multidisciplinary Cancer Care (BMC Cancer)

13. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained